Helus Pharma Stock
Helus Pharma Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- Canada
- CEO
- Michael I. Halstead
- Employees
- 100
- Market cap
- $654 M
- IPO
- 13/09/2019
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Helus Pharma stock: price history
1D
-4.5%
1W
-10.6%
1M
-21.7%
6M
+91.8%
YTD
+29.0%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~5% stronger price swings than usual
Helus Pharma stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Cybin Inc. is a biopharmaceutical company in the clinical development stage focused on developing novel therapeutic agents based on psychedelic compounds. Its research portfolio includes CYB003 for the treatment of depression and CYB004 for the therapy of anxiety disorders, among others. As the company is in an early development stage, the current emphasis is on clinical trials and validation of the research pipeline rather than on active sales activities.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Helus Pharma
Analyst assessment of Helus Pharma
PRICE TARGET LOW
US$15.00
CONSENSUS
US$22.00
MEDIAN
US$16.00
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 20/08/2026
Helus Pharma stock metrics
P/E
-2.53
P/B
2.3
EV/EBITDA
-0.55
RETURN ON EQUITY
-19.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.5%
FLOAT SHARES
48,686,589
AVG. DAILY VOLUME (30D)
1,693,898
Insider transactions (SEC)
So Eric H. L.
Cavers Greg
Glavine Paul
Halstead Michael
Glavine Paul
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.5%
Forums (Reddit)
See the full forum history with Pro.
Comparable stocks
Frequently asked questions about Helus Pharma stock
What does Helus Pharma do?
Helus Pharma Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Canada.
The CEO is Michael I. Halstead, the company employs around 100 people.
The IPO was on 13/09/2019; the stock trades on NASDAQ under the ticker HELP.
What do analysts say about Helus Pharma stock?
4 analysts rate the stock, the consensus is Buy (as of 20/08/2026).
The average price target is US$22.00, ranging from US$15.00 to US$35.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
When does Helus Pharma report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Helus Pharma pay a dividend?
No, Helus Pharma currently does not pay a dividend.
Which stocks are comparable to Helus Pharma?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Bausch + Lomb, AbCellera Biologics, Eli Lilly and Company, Johnson & Johnson and AbbVie.
How can I get Helus Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Helus Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.